Xiamen Winbio Biotechnology: Deeply Rooted in Biotechnology, Pioneering a Specialized, Sophisticated, and Innovative Path in the IVD Raw Materials Sector
Release date:
2025-09-16
Author:
Source:
In the Biomedical Port Area of Haicang District, Xiamen, Xiamen Winbio Biotechnology Co., Ltd., a high-tech enterprise dedicated to the field of in vitro diagnostic (IVD) raw materials, has, since its establishment in 2014, leveraged its deep technical expertise and relentless spirit of innovation to become a key player among domestic IVD raw material suppliers.
In the Biomedical Port Area of Haicang District, Xiamen, Xiamen Winbio Biotechnology Co., Ltd., a high-tech enterprise dedicated to the field of in vitro diagnostic (IVD) raw materials, has, since its establishment in 2014, leveraged its deep technical expertise and relentless spirit of innovation to become a key player among domestic IVD raw material suppliers.
Enterprise Startup and Foundation Building
Xiamen Winbio Biotechnology Co., Ltd. was established on June 19, 2014, with its registered address in Haicang District, Xiamen, and its legal representative is Xu Miaowei. The company was formerly known as “Xiamen Saiyue Biotechnology Co., Ltd.” It has a registered capital of RMB 5 million, with RMB 1.01 million paid up.
At its inception, the company was primarily engaged in technology promotion and application services. Leveraging its keen insight into the biotechnology sector, it gradually defined its strategic direction.
Focusing on IVD raw materials to build a technological core.
The core team of Winbio Biotech comprises seasoned technical experts with years of R&D experience, as well as a number of key technical personnel who have hands-on expertise across the upstream and downstream segments of in vitro diagnostic reagent development. The company is committed to providing high-quality active raw materials—such as antigens and antibodies—and comprehensive technical solutions for diverse application platforms.
Its product portfolio spans protein recombinant technology, antibody R&D, manufacturing, and raw material applications, encompassing assay platforms such as chemiluminescence, ELISA, fluorescence, and colloidal gold. The company has launched well‑established, stable raw materials and application‑specific solutions across infectious disease, inflammation, and respiratory‑related product lines, as well as secondary antibodies. Additionally, it has amassed extensive expertise in the stability of four‑marker blood screening assays, hepatitis B serological tests, inflammatory‑related products, and complete reagent kits.
Expansion of Scale and Relocation to a New Site
With the rapid growth of its business, and in order to expand production capacity and meet customer demand, Winbio Biotechnology held a grand relocation ceremony on June 30, 2022, at the Bio-Industry Collaborative Innovation and Entrepreneurship Center in Haicang District, Xiamen.
At the celebration, General Manager Liu Jie stated that this relocation marks a significant milestone in Winbio Bio’s development and serves as a new platform for the company to set sail. At present, the company’s total office space has reached 1,538.92 square meters, including 967 square meters dedicated to laboratory facilities. The premises are equipped with three Class 100,000 cleanrooms totaling 120 square meters and two Class 10,000 cleanrooms spanning 30 square meters.
Innovation-driven, with honors to accompany it.
The development of Winbio Biotechnology can be described as a journey driven by innovation, replete with numerous accolades:
2019: Successfully developed a native Mycoplasma pneumoniae antigen, becoming the second company worldwide—after the U.S.-based Meridian—to possess in-house R&D and manufacturing capabilities for this key antigen used in diagnostic kits, thereby breaking the foreign monopoly on commercially available native Mycoplasma pneumoniae antigens.
2020: During the pandemic response, the company was selected by the Xiamen Science and Technology Bureau as a key supporting entity for epidemic prevention and control; in the same year, it was awarded the title of “Xiamen Municipal High-Tech Enterprise.”
2021: Awarded the title of “National High-Tech Enterprise”; its “Core Materials for Rapid Antigen–Antibody Biosensing” project was recognized as a 2021 Xiamen Municipal High-Tech Achievement Transformation Project; and in the same year, it was granted the “Outstanding Supplier” designation by Beijing Rejing Biotechnology Co., Ltd.
2022: In June, the company was recognized as a “Specialized, Refined, Distinctive, and Innovative SME” by the Xiamen Municipal Bureau of Industry and Information Technology; in July, it was awarded recognition as a 2021 Xiamen High-Tech Achievement Transformation Project; and in September, it was registered as a technology-based SME.
2024: In December, the company successfully passed the re‑review for “National High‑Tech Enterprise” status.
In the field of intellectual property, the company has been granted 16 utility model patents and 2 invention patents. As of December 2024, the company holds a total of 20 patents and 5 registered trademarks. In 2023, its R&D expenditure exceeded RMB 2 million, and it was included on Xiamen City’s “whitelist” of enterprises eligible for the Technology Innovation Fund.
Business Expansion and Group-Based Development
As the company continues to grow, Winbio Biotechnology has also begun making external investments to expand its business scope:
According to big‑data analysis by Tianyancha, Xiamen Winbio Biotechnology Co., Ltd. has made external investments in a total of three companies. In 2022, it established Xiamen Winbio Gene Technology Co., Ltd. (holding a 65% stake) and Xiamen Winbio Medical Technology Co., Ltd.
Winbio Gene is dedicated to the development of human genetic diagnostic and therapeutic technologies, as well as medical research and experimental development, marking a further deepening and expansion of Winbio Bio’s strategic positioning in the biotechnology sector.
Looking ahead
Rooted in innovation and committed to excellence, Winbio Biotechnology has consistently upheld its corporate mission of becoming a “trusted partner for raw materials and application solutions” to its customers. Throughout its evolution, Winbio Biotechnology has not only witnessed the rapid growth of China’s IVD industry but has also, through its expertise and innovative spirit, contributed to breaking foreign technology monopolies and strengthening the resilience of China’s biopharmaceutical industry’s value chain and supply chain.
Looking ahead, as the global biopharmaceutical industry continues to advance and market demand keeps growing, Xiamen Winbio Biotechnology Co., Ltd., which specializes in IVD raw materials and technology solutions, is poised for promising prospects.
Previous page:
Leave a Message Online
Please provide the correct information, and we will contact you promptly!